Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies

Journal of Virology

Volumn 88, Issue 21, 2014, Pages 12623-12643

  Hraber, Peter ^a   Korber, Bette T ^a,b   Lapedes, Alan S ^a   Bailer, Robert T ^c   Seaman, Michael S ^d   Gao, Hongmei ^e   Greene, Kelli M ^e   McCutchan, Francine ^f   Williamson, Carolyn ^g   Kim, Jerome H ^f   Tovanabutra, Sodsai ^f   Hahn, Beatrice H ^h   Swanstrom, Ronald ⁱ   Thomson, Michael M ^j   Gao, Feng ^e   Harris, Linda ^k   Giorgi, Elena ^a   Hengartner, Nicholas ^a   Bhattacharya, Tanmoy ^a,l   Mascol, John R ^a,c   Montefiori, David C ^e   more..

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b NEW MEXICO CONSORTIUM   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k Fred Hutchinson Cancer Research Center   (United States)

^l SANTA FE INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

AFRICA; AGE; ANTIBODY RESPONSE; ARTICLE; ASIA; CHINA; CLADISTICS; CONTROLLED STUDY; EUROPE; GENETIC VARIABILITY; GEOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 ENV PSEUDOTYPED VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; UNINDEXED SEQUENCE; UNITED STATES; VACCINATION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION; BLOOD; CLASSIFICATION; EPIDEMIC; GENETICS; GENOTYPE; HEALTH; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; TIME; VIROLOGY;

ANTIBODIES, NEUTRALIZING; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPIDEMICS; GENOTYPE; GEOGRAPHY; GLOBAL HEALTH; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; TIME FACTORS;

EID: 84907993259     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01705-14     Document Type: Article

References (111)

1. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888. http://dx.doi.org /10.1126/science.280.5371.1884.
2. Hemelaar J. 2013. Implications of HIV diversity for the HIV-1 pandemic. J. Infect. 66:391-400. http://dx.doi.org/10.1016/j.jinf.2012.10.026.
3. Hemelaar J, Gouws E, Ghys PD, Osmanov S. 2011. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25:679-689. http://dx.doi.org/10.1097/QAD.0b013e328342ff93.
4. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessments of neutralizing antibodies. J. Virol. 84:1439-1452. http://dx.doi.org/10.1128/JVI.02108-09.
5. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH. 2012. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206:431-441. http://dx.doi.org/10.1093 /infdis/jis367.
6. Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D' Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, Berman PW, Self SG, Montefiori DC. 2010. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 202:595-605. http://dx.doi.org /10.1086/654816.
7. Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, Mc-Elrath MJ, Hural J, De Rosa SC, Sato A, Huang Y, Frey SE, Sato P, Donnelly J, Barnett S, Corey LJ, HIV Vaccine Trials Network of NIAID. 2011. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J. Infect. Dis. 203:1165-1173. http://dx.doi.org/10.1093/infdis/jiq175.
8. Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, Caudrelier El Habib R, Klein M, Lazzarin A, Stablein DM, Deers M, Corey L, Greenberg ML, Schwartz DH, Montefiori DC. 2000. Immunization with recombinant canarypox vectors expressing membraneanchored gp120 followed by gp160 protein boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 16:2019-2035. http: //dx.doi.org/10.1089/088922200750054756.
9. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340-348. http://dx.doi.org/10.1093/infdis/173.2.340.
10. Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, Stablein DM, Twaddell T, Berman PW, Gregory T, Izu AE, Walker MC, Fast P. 1994 Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 272:475-480. http://dx.doi.org/10.1001/jama.272.6.475.
11. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K, Bangkok Vaccine Evaluation Group. 2006. Randomized, double-blind, placebocontrolled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injecting drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671. http://dx.doi.org/10.1086/508748.
12. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp120 HIV Vaccine Study Group. 2005. Placebo-controlled phase 3 trial of recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654-665. http://dx.doi.org/10.1086/428404.
13. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB. 2013. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369:2083-2092. http://dx.doi.org/10.1056/NEJMoa1310566.
14. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao H-X, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286. http: //dx.doi.org/10.1056/NEJMoa1113425.
15. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220. http://dx.doi.org/10.1056/NEJMoa0908492.
16. Stamatatos L, Morris L, Burton DR, Mascola JR. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15:866-870. http://dx.doi.org/10.1038/nm.1949.
17. Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. 2014. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28:163-169. http://dx.doi.org/10.1097 /QAD.0000000000000106.
18. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L, the CAPRISA 002 Study Team. 2011. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4 T cell decline and high viral load during acute infection. J. Virol. 85:4828-4840. http://dx.doi.org/10.1128/JVI.00198-11.
19. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool-Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L. 2011. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85:11502-11519. http: //dx.doi.org/10.1128/JVI.05363-11.
20. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348. http://dx.doi.org/10.1128/JVI.00110-09.
21. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83: 757-769. http://dx.doi.org/10.1128/JVI.02036-08.
22. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R. 2009. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83:1045-1059. http://dx.doi.org/10.1128/JVI.01992-08.
23. Doria-Rose NA, Klein RM, Manion MM, O' Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, Mascola JR, Connors M. 2009. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 83: 188-199. http://dx.doi.org/10.1128/JVI.01583-08.
24. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with humanimmunodeficiency virus type 1 subtypesBand C. J. Virol. 82:11651-11668 http://dx.doi.org/10.1128/JVI.01762-08.
25. Corti D, Lanzavecchia A. 2013. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31:705-742. http://dx.doi.org/10.1146 /annurev-immunol-032712-095916.
26. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. 2013. Antibodies in HIV-1 vaccine development and therapy. Science 341:1199-1204. http://dx.doi.org/10.1126/science.1241144.
27. Kwong PD, Mascola JR. 2012. Human antibodies that neutralize HIV: identification, structures, and B cell ontogenies. Immunity 37:412-425. http://dx.doi.org/10.1016/j.immuni.2012.08.012.
28. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R. 2012. A blueprint for HIV vaccine discovery. Cell Host Microbe 12:396-407. http://dx.doi.org/10.1016/j.chom.2012.09.008.
29. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Peña AT, Cupo A, Julien JP, van Gils M, Lee PS, Peng W, Paulson JC, Poignard P, Burton DR, Moore JP, Sanders RW, Wilson IA, Ward AB. 2014. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40:669-680 http://dx.doi.org/10.1016/j.immuni.2014.04.008.
30. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811-817. http://dx.doi.org/10.1126/science.1192819.
31. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O' Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, Haynes BF. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85:9998-10009. http://dx.doi.org/10.1128/JVI.05045-11.
32. Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, Georgiev IS, Altae-Tran HR, Chuang GY, Joyce MG, Do Kwon Y, Longo NS, Louder MK, Luongo T, McKee K, Schramm CA, Skinner J, Yang Y, Yang Z, Zhang Z, Zheng A, Bonsignori M, Haynes BF, Scheid JF, Nussenzweig MC, Simek M, Burton DR, Koff WC, NISC Comparative Sequencing Program, Mullikin JC, Connors M, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. 2013. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39:245-258. http://dx.doi.org/10.1016/j.immuni.2013.04.012.
33. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, MacPherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR. 2013. Rational HIV immunogen design to target specific germline B cell receptors. Science 340:711-716. http://dx.doi.org/10.1126/science.1234150.
34. McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, Jardine J, Menis S, Scheid JF, West AP, Schief WR, Stamatatos L. 2013. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 210: 655-633. http://dx.doi.org/10.1084/jem.20122824.
35. Liao H-X, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, Zhu J, Shapiro L, NISC Comparative Sequencing Program, Mullikin JC, Gnanakaran S, Hraber P, Wiehe K, Kelsoe G, Yang G, Xia SM, Montefiori DC, Parks R, Lloyd KE, Scearce RM, Soderberg KA, Cohen M, Kamanga G, Louder MK, Tran LM, Chen Y, Cai F, Chen S, Moquin S, Du X, Joyce MG, Srivatsan S, Zhang B, Zheng A, Shaw GM, Hahn BH, Kepler TB, Korber BT, Kwong PD, Mascola JR, Haynes BF. 2013. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496: 469-476. http://dx.doi.org/10.1038/nature12053.
36. Korber B, Gnanakaran S. 2009. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr. Opin. HIV AIDS 4:408-417. http://dx.doi.org/10.1097/COH.0b013e32832f129e.
37. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30:423-433. http://dx.doi.org/10.1038/nbt.2197.
38. Kwong PD, Mascola JR, Nabel GJ. 2013. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat. Rev. Immunol. 13:693-701. http://dx.doi.org/10.1038/nri3516.
39. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236 http://dx.doi.org/10.1038/ni0304-233.
40. Douek DC, Kwong PD, Nabel GJ. 2006. The rational design of an AIDS vaccine. Cell 124:677-681. http://dx.doi.org/10.1016/j.cell.2006.02.005.
41. Sanders RW, Derking R, Cupo A, Julien J-P, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Peña AT, Korzun J, Golabek M, de los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP. 2013. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9(9): e1003618. http://dx.doi.org/10.1371/journal.ppat.1003618.
42. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. 2005. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 14:59-67.
43. Fernando K, Hu H, Ni H, Hoxie JA, Weissman D. 2007. Vaccinedelivered HIV envelope inhibits CD4+ T-cell activation, a mechanism for poor HIV vaccine responses. Blood 109:2538-2544. http://dx.doi.org /10.1182/blood-2006-08-038661.
44. Shan M, Klasse PJ, Banerjee K, Dey AK, Iyer SPN, Dionisio R, Charles D, Campbell-Gardener L, Olson WC, Sanders RW, Moore JP. 2007. HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog. 3(11):e169. http://dx.doi.org/10.1371/journal.ppat.0030169.
45. He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, Knowles DM, Moore JP, Cerutti A. 2006. HIV-1 envelope triggers polyclonal IgG class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J. Immunol. 176:3931-3941. http://dx.doi.org/10.4049/jimmunol.176.7.3931.
46. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. 1996. Inter-and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:427-444.
47. Mascola JR, Louder MK, Surman SR, VanCott TC, Yu XF, Bradac J, Porter KR, Nelson KE, Girard M, McNeil JG, McCutchan FE, Birx DL, Burke DS. 1996. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res. Hum. Retroviruses 12:1319-1328. http://dx.doi.org/10.1089/aid.1996.12.1319.
48. Mascola JR, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA, Wagner KF, Fowler AK, McNeil JG, Burke DS. 1994. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J. Infect. Dis. 169:48-54. http://dx.doi.org/10.1093/infdis/169.1.48.
49. Nyambi PN, Nkengasong J, Lewi P, Andries K, Janssens W, Fransen K, Heyndrickx L, Piot P, van der Groen G. 1996. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J. Virol. 70: 6235-6243.
50. Weber J, Fenyö EM, Beddows S, Kaleebu P, Björndal Å. 1996. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. J. Virol. 70:7827-7832.
51. Brown BK, Wiecaorek L, Sanders-Buell E, Borges AR, Robb ML, Birx DL, Michael NL, McCutchan FE, Polonis VR. 2008. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375:529-538. http://dx.doi.org/10.1016/j.virol.2008.02.022.
52. Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, Karim SA, Montefiori DC. 2002. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J. Virol. 76:2233-2244. http://dx.doi.org/10.1128/jvi.76.5.2233-2244.2002.
53. Binley J, Wrin T, Korber B, Zwick M, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos C, Burton D. 2004. Comprehensive cross-subtype neutralization analysis of a panel of antihuman immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78: 13232-13252. http://dx.doi.org/10.1128/JVI.78.23.13232-13252.2004.
54. Kulkarni SS, Lapedes A, Tang H, Gnanakaran S, Daniels MG, Zhang M, Bhattacharya T, Li M, Polonis VR, McCutchan FE, Morris L, Ellenberger D, Butera ST, Bollinger RC, Korber BT, Paranjape RS, Montefiori DC. 2009. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C human immunodeficiency virus type 1 env clones from India. Virology 385:505-520. http://dx.doi.org/10.1016/j.virol.2008.12.032.
55. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou JT, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber BTM, Hunter E, Hahn BH, Montefiori DC. 2006. Genetic and neutralization properties of subtypeChuman immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa. J. Virol. 80:11776-11790 http://dx.doi.org/10.1128/JVI.01730-06.
56. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
57. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien J-P, Wang S-K, Ramos A, Chan-Hui P-Y, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong C-H, Phogat S, Wrin T, Simek MD, Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-478. http://dx.doi.org/10.1038/nature10373.
58. deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, Zolla-Pazner S, LaBranche CC, Mascola JR, Korber BT, Montefiori DC. 2014. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 88:2489-2507. http://dx.doi.org/10.1128 /JVI.02853-13.
59. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871-1879. http://dx.doi.org/10.1097/00002030-200309050-00005.
60. Montefiori DC. 2009. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485:395-405. http://dx.doi.org/10.1007/978-1-59745-170-3_26.
61. Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, Gao H, Todd CA, Ozaki DA, Seaman MS, Mascola JR, Montefiori DC. 2014 Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409C:131-146.
62. Todd CA, Greene KM, Yu X, Ozaki DA, Gao H, Huang Y, Wang M, Li G, Brown R, Wood B, D' Souza MP, Gilbert P, Montefiori DC, Sarzotti-Kelsoe M. 2012. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. J. Immunol. Methods 375:57-67. http://dx.doi.org/10.1016/j.jim.2011.09.007.
63. Eddy SR. 1998. Profile hidden Markov models. Bioinformatics 14:755-763 http://dx.doi.org/10.1093/bioinformatics/14.9.755.
64. Rambaut A. 2002. Se-Al. Sequence Alignment Editor v2.0a11. http://tree.bio.ed.ac.uk/software/seal/.
65. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. 2010. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol. 59:307-321 http://dx.doi.org/10.1093/sysbio/syq010.
66. Nickle DC, Heath L, Jensen MA, Gilbert PB, Mullins JI, Kosakovsky-Pond SL. 2007. HIV-specific probabilistic models of protein evolution. PLoS One 2:e503. http://dx.doi.org/10.1371/journal.pone.0000503.
67. R Core Team. 2013. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http: //www.r-project.org.
68. Paradis E, Claude J, Strimmer K. 2004. APE: analyses of phylogenetics and evolution in R language. Bioinformatics 20:289-290. http://dx.doi.org/10.1093/bioinformatics/btg412.
69. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, Daniels M, Ferrari G, Haynes BF, McMichael A, Shaw GM, Hahn BH, Korber B, Seoighe C. 2009. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog. 5:e1000414. http://dx.doi.org/10.1371/journal.ppat.1000414.
70. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557. http://dx.doi.org/10.1073 /pnas.0802203105.
71. McLeod AI. 2011. Kendall: Kendall rank correlation and Mann-Kendall trend test. R package version 2.2. http://cran.r-project.org/package=Kendall.
72. Dabney A, Storey JD. 2013. qvalue: q-value estimation for false discovery rate control. http://bioconductor.org/packages/release/bioc/html /qvalue.html.
73. Storey JD, Tibshirani R. 2003. Statistical significance for genome-wide experiments. Proc. Natl. Acad. Sci. U. S. A. 100:9440-9445. http://dx.doi.org/10.1073/pnas.1530509100.
74. Crawley MJ. 2002. Statistical computing: an introduction to data analysis using S-Plus. John Wiley and Sons, Inc., New York, NY.
75. Bates D, Maechler M, Bolker B, Walker S. 2013. lme4: linear mixedeffects models using Eigen and S4. https://github.com/lme4/lme4/.
76. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, Learn GH, Leitner T, McCutchan F, Osmanov S, Peeters M, Pieniazek D, Salminen M, Sharp PM, Wolinsky S, Korber B. 2000. HIV-1 nomenclature proposal. Science 288:55-56. http://dx.doi.org/10.1126/science.288.5463.55d.
77. Siepel AC, Halpern AL, Macken C, Korber BT. 1995. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res. Hum. Retroviruses 11:1413-1416. http://dx.doi.org/10.1089/aid.1995.11.1413.
78. Su L, Graf M, Zhang Y, von Briesen H, Xing H, Köstler J, Melzl H, Wolf H, Shao Y, Wagner R. 2000. Characterization of a virtually fulllength human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B' ) recombinant strain in China. J. Virol. 74:11367-11376 http://dx.doi.org/10.1128/JVI.74.23.11367-11376.2000.
79. Zhang M, Foley B, Schultz AK, Macke JP, Bulla I, Stanke M, Morgenstern B, Korber B, Leitner T. 2010. The role of recombination in the emergence of a complex and dynamic HIV epidemic. Retrovirology 7:25. http://dx.doi.org/10.1186/1742-4690-7-25.
80. Carr JK, Salminen MO, Koch C, Gotte D, Artenstein AW, Hegerich PA, St Louis D, Burke DS, McCutchan FE. 1996. Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J. Virol. 70:5935-5943.
81. Anderson JP, Rodrigo AG, Learn GH, Madan A, Delahunty C, Coon M, Girard M, Osmanov S, Hood L, Mullins JI. 2000. Testing the hypothesis of a recombinant origin of human immunodeficiency virus type 1 subtype E. J. Virol. 74:10752-10765. http://dx.doi.org/10.1128 /JVI.74.22.10752-10765.2000.
82. Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y, Zhang B, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Amin MN, Wang LX, Burton DR, Koff WC, Nabel GJ, Mascola JR, Bewley CA, Kwong PD. 2013. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat. Struct. Mol. Biol. 20:804-813. http://dx.doi.org/10.1038/nsmb.2600.
83. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O' Dell S, Patel N, Shahzad-ul Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-343. http://dx.doi.org/10.1038/nature10696.
84. Liao H-X, Chen X, Munshaw S, Zhang R, Marshall DJ, Vandergrift N, Whitesides JF, Lu X, Yu JS, Hwang KK, Gao F, Markowitz M, Heath SL, Bar KJ, Goepfert PA, Montefiori DC, Shaw GC, Alam SM, Margolis DM, Denny TN, Boyd SD, Marshal E, Egholm M, Simen BB, Hanczaruk B, Fire AZ, Voss G, Kelsoe G, Tomaras GD, Moody MA, Kepler TB, Haynes BF. 2011. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J. Exp. Med. 208:2237-2249. http://dx.doi.org/10.1084/jem.20110363.
85. Mascola JR, D' Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC. 2005. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79:10103-10107. http://dx.doi.org/10.1128/JVI.79.16.10103-10107.2005.
86. Doria-Rose NA, Klein RM, Daniels MG, O' Dell S, Nason M, Lapedes A, Bhattacharya T, Migueles SA, Wyatt RT, Korber BT, Mascola JR, Connors M. 2010. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631-1636. http://dx.doi.org/10.1128/JVI.01482-09.
87. Meng Z, Xin R, Zhong P, Zhang C, Abubakar YF, Li J, Liu W, Zhang X, Xu J. 2012. A new migration map of HIV-1 CRF07_BC in China: analysis of sequences from 12 provinces over a decade. PLoS One 7:e52373. http://dx.doi.org/10.1371/journal.pone.0052373.
88. Tee KK, Pybus OG, Li XJ, Han X, Shang H, Kamarulzaman A, Takebe Y. 2008. Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08_BC and 07_BC in Asia. J. Virol. 82:9206-9215. http://dx.doi.org/10.1128/JVI.00399-08.
89. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn BH, Wolinsky S, Bhattacharya T. 2000. Timing the ancestor of the HIV-1 pandemic strains. Science 288:1789-1796. http://dx.doi.org/10.1126/science.288.5472.1789.
90. Kalish ML, Korber BT, Pillai S, Robbins KE, Leo YS, Saekhou A, Verghese I, Gerrish P, Goh CL, Lupo D, Tan BH, Brown TM, Chan R. 2002 The sequential introduction of HIV-1 subtype B and CRF01AE in Singapore by sexual transmission: accelerated V3 region evolution in a subpopulation of Asian CRF01 viruses. Virology 304:311-329. http://dx.doi.org/10.1006/viro.2002.1691.
91. Kalish ML, Robbins KE, Pieniazek D, Schaefer A, Nzilambi N, Quinn TC, St Louis ME, Youngpairoj AS, Phillips J, Jaffe HW, Folks TM. 2004 Recombinant viruses and early global HIV-1 epidemic. Emerg. Infect. Dis. 10:1227-1234.
92. Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K, Bunce M, Muyembe JJ, Kabongo JM, Kalengayi RM, Van Marck E, Gilbert MT, Wolinsky SM. 2008. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 455:661-664. http://dx.doi.org/10.1038/nature07390.
93. Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Nitayaphan S, Andrews C, O' Connell RJ, Yang ZY, Nabel GJ, Kim JH, Michael NL, Montefiori DC, Liao H-X, Haynes BF, Tomaras GD. 2014. Vaccine-induced IgG antibodies to V1V2 regions of multiple 1 HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 9:e87572. http://dx.doi.org/10.1371/journal.pone.0087572.
94. Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC. 2013. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 8:e75665. http: //dx.doi.org/10.1371/journal.pone.0075665.
95. Yates NL, Liao H-X, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O' Connell RJ, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Pinter A, Zolla-Pazner S, Gilbert PB, Nabel GJ, Michael NL, Kim JH, Montefiori DC, Haynes BF, Tomaras GD. 2014. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci. Transl. Med. 6:228ra39. http://dx.doi.org/10.1126 /scitranslmed.3007730.
96. Hu DJ, Subbarao S, Vanichseni S, Mock PA, Ramos A, Nguyen L, Chaowanachan T, Griensven Fv Choopanya K, Mastro TD, Tappero JW. 2005. Frequency of HIV-1 dual subtype infections, including intersubtype superinfections, among injection drug users in Bangkok, Thailand. AIDS 19:303-308.
97. Yerly S, Jost S, Monnat M, Telenti A, Cavassini M, Chave JP, Kaiser L, Burgisser P, Perrin L, Swiss HIV Cohort Study. 2004. HIV-1 co/ superinfection in intravenous drug users. AIDS 18:1413-1421. http://dx.doi.org/10.1097/01.aids.0000131330.28762.0c.
98. Templeton AR, Kramer MG, Jarvis J, Kowalski J, Gange S, Schneider MF, Shao Q, Zhang GW, Yeh MF, Tsai HL, Zhang H, Markham RB. 2009 Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women. Retrovirology 6:54. http://dx.doi.org/10.1186 /1742-4690-6-54.
99. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019-2022 http://dx.doi.org/10.1126/science.1093137.
100. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J. 2005. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J. Virol. 79:6528-6531. http://dx.doi.org/10.1128/JVI.79.10.6528-6531.2005.
101. Liu Y, Curlin ME, Diem K, Zhao H, Ghosh AK, Zhu H, Woodward AS, Maenza J, Stevens CE, Stekler J, Collier AC, Genowati I, Deng W, Zioni R, Corey L, Zhu T, Mullins JI. 2008. Env length and N-linked glycosylation following transmission of human immunodeficiency virus type 1 subtype B viruses. Virology 374:229-233. http://dx.doi.org/10.1016/j.virol.2008.01.029.
102. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP, Jr, Bjorkman PJ, Wilen CB, Doms RW, O' Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, Shaw GM, Hahn BH. 2013 Phenotypic properties of transmitted founder HIV-1. Proc. Natl. Acad. Sci. U. S. A. 110:6626-6633. http://dx.doi.org/10.1073/pnas.1304288110.
103. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, Shen T, Gaschen B, Krishnamoorthy M, Li H, Decker JM, Salazar-Gonzalez JF, Wang S, Jiang C, Gao F, Swanstrom R, Anderson JA, Ping LH, Cohen MS, Markowitz M, Goepfert PA, Saag MS, Eron JJ, Hicks CB, Blattner WA, Tomaras GD, Asmal M, Letvin NL, Gilbert PB, Decamp AC, Magaret CA, Schief WR, Ban YE, Zhang M, Soderberg KA, Sodroski JG, Haynes BF, Shaw GM, Hahn BH, Korber B. 2011 Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 7:e1002209. http://dx.doi.org/10.1371/journal.ppat.1002209.
104. Asmal M, Hellmann I, Liu W, Keele BF, Perelson AS, Bhattacharya T, Gnanakaran S, Daniels M, Haynes BF, Korber BT, Hahn BH, Shaw GM, Letvin NL. 2011. A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. PLoS One 6:e23673. http://dx.doi.org/10.1371/journal.pone.0023673.
105. Zhang H, Rola M, West JT, Tully DC, Kubis P, He J, Kankasa C, Wood C. 2010. Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. Virology 400:164-174. http://dx.doi.org/10.1016/j.virol.2009.12.019.
106. Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Petersen JE, Wojcechowskyj JA, Sodroski J, Haynes BF, Montefiori DC, Tilton JC, Shaw GM, Hahn BH, Doms RW. 2011. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J. Virol. 85:8514-8527. http://dx.doi.org /10.1128/JVI.00736-11.
107. Bar KJ, Tsao CY, Iyer SS, Decker JM, Yang Y, Bonsignori M, Chen X, Hwang KK, Montefiori DC, Liao HX, Hraber P, Fischer W, Li H, Wang S, Sterrett S, Keele BF, Ganusov VV, Perelson AS, Korber BT, Georgiev I, McLellan JS, Pavlicek JW, Gao F, Haynes BF, Hahn BH, Kwong PD, Shaw GM. 2012. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog. 8:e1002721. http://dx.doi.org/10.1371/journal.ppat.1002721.
108. Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, Morris L, Moore PL. 2013. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 9:e1003738. http://dx.doi.org/10.1371/journal.ppat.1003738.
109. Haim H, Strack B, Kassa A, Madani N, Wang L, Courter JR, Princiotto A, McGee K, Pacheco B, Seaman MS, Smith AB, III, Sodroski J. 2011. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog. 7:e1002101. http://dx.doi.org/10.1371/journal.ppat.1002101.
110. Haim H, Salas I, McGee M, Eichelberger N, Winter E, Pacheco B, Sodroski J. 2013. Modeling virus-and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency. Cell Host Microbe 14:547-558. http://dx.doi.org/10.1016/j.chom.2013.10.006.
111. Robbins KE, Lemey P, Pybus OG, Jaffe HW, Youngpairoj AS, Brown TM, Salemi M, Vandamme AM, Kalish ML. 2003. U.S. human immunodeficiency virus type 1 epidemic: date of origin, population history, and characterization of early strains. J. Virol. 77:6359-6366. http://dx.doi.org/10.1128/JVI.77.11.6359-6366.2003.